Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate.

The Sheffield Trophoblastic Disease Centre treats about 25 patients with persistent trophoblastic disease each year. A total of 75% of patients are classified as low risk according to the Charing Cross Hospital prognostic scoring system and receive methotrexate (MTX) 50 mg, i.m., on days 1, 3, 5, 7...

Descripción completa

Detalles Bibliográficos
Autores principales: Gillespie, A. M., Lorigan, P. C., Radstone, C. R., Waterhouse, J. C., Coleman, R. E., Hancock, B. W.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1997
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228140/
https://www.ncbi.nlm.nih.gov/pubmed/9374387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228140/
https://www.ncbi.nlm.nih.gov/pubmed/9374387

Ejemplares similares